Bio-Gene Technology (ASX:BGT) ROE % Adjusted to Book Value : -23.18% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Bio-Gene Technology ROE % Adjusted to Book Value?

Bio-Gene Technology's ROE % for the quarter that ended in Dec. 2024 was -142.34%. Bio-Gene Technology's PB Ratio for the quarter that ended in Dec. 2024 was 6.14. Bio-Gene Technology's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -23.18%.

Bio-Gene Technology ROE % Adjusted to Book Value Historical Data

The historical data trend for Bio-Gene Technology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Gene Technology ROE % Adjusted to Book Value Chart

Bio-Gene Technology Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-10.86

-7.70

-17.49

-15.07

-22.90

Bio-Gene Technology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial										-17.84	-13.78	-26.23	-15.87	-23.18

Competitive Comparison of Bio-Gene Technology's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Bio-Gene Technology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Gene Technology's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Bio-Gene Technology's ROE % Adjusted to Book Value falls into.

Bio-Gene Technology ROE % Adjusted to Book Value Calculation

Bio-Gene Technology's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-80.14%	/	3.50
	=	-22.90%

Bio-Gene Technology's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-142.34%	/	6.14
	=	-23.18%

Bio-Gene Technology ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Bio-Gene Technology's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Gene Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Gene Technology Ltd (ASX:BGT) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000

Website

https://www.bio-gene.com.au

Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance. Its products are Flavocide and Qcide which include a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. The group's product has multiple applications across public health, crop protection, grain storage, and consumer use. It provides new options derived from nature to meet market demand for effective and safe pest management solutions.

Bio-Gene Technology Headlines

From GuruFocus

Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

By Business Wire Business Wire • 12-20-2021